NAMSA celebrated Cochlear receiving FDA clearance for the new Osia 3 Sound Processor, the first fully rechargeable active bone conduction sound processor designed for children and adults with conductive hearing loss, mixed hearing loss, and single-sided deafness.
Published
Signal category
Legal & Regulatory
Quote
“Cochlear! We're excited to celebrate Cochlear for receiving FDA clearance for the new Osia® 3 Sound Processor”
— NAMSA team
Company
- Industry
- Business Consulting and Services
- Location
- Toledo, US
- Company size
- 1,690 employees
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Learn more: https://namsa.com/about/client-testimonials/
Founded 1967